# Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

> **NCT02227849** · PHASE4 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 71 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Canagliflozin (TA-7284)
- **DRUG:** GLP-1 analogue

## Key facts

- **NCT ID:** NCT02227849
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227849, "Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02227849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*